Analysis: Stocks

LEG Immobilien: Capex and refinancing weigh on the semester's AFFO

Earnings/Sales releases LEG reported a mixed second quarter: resilient rental growth was offset by temporary pressure on cash earnings due to CapEx timing and higher refinancing costs. The group...

Travis Perkins: H1 shows operational progress; merchanting recovery awaited

Earnings/Sales Releases Travis Perkins' H1 FY26 results were mixed, with Q2 Merchanting sales stabilising and adjusted operating profit beating consensus by around 11%, supported by stronger gross...

Rising Margins Help Sekisui House Outrun Housing Slump

The company's playbook is working but investors are increasingly questioning how durable that advantage really is.

Mao Geping is Chasing Beauty's Boom

Mao Geping Cosmetics Co., Ltd.'s latest results paint a picture of a beauty brand still enjoying strong consumer demand, although how long can that momentum last?

CarTrade Tech Turns Broad-Based Growth into Bigger Margins

CarTrade Tech's expands its platform ecosystem alongside India's vehicle market, with investors' attention increasingly turning towards its growth.

Hsbc: Impressive capital generation

Earnings/Sales releases The group posted a good set of results driven by strong top-line momentum, whereas the group continued to enjoy cost savings and benign Asset quality trends. The quarter...

Salvatore Ferragamo Still Waiting for a Recovery

The reinvention of the Italian shoemaker and leather goods maker, which had started losing its footing well before the downturn in the luxury sector, is dragging on with no visible signs of...

PUMA: Recovery still to come

Earnings/sales releases Puma delivered a modestly better than expected Q2, with sales and profitability ahead of consensus expectations, highlighting an encouraging improvement in gross margin. FY 26...

Beiersdorf: NIVEA's weakness triggers a reset

Earnings/Sales Releases Beiersdorf unexpectedly released its H1 figures alongside a downgrade to FY26 guidance. Q2 organic sales declined by 2.3%, while H1 profitability came in below expectations....

Umicore: A bearish stance on metals

Earnings/Sales releases Umicore posted strong results for H1 2026, driven by market share gains in Catalysis and a metals rally in Q1. However, we see a repeat of H1 in the second half as unlikely....

Forvia: Solid H1 beat despite China underperformance; FY26 guidance confirmed, deleveraging on track

Earnings/Sales releases Forvia's H1 results exceeded expectations, though the beat was of low quality. Forvia outperformed in Europe and the Americas, while performance in China remained weak due to...

Imerys: H1 2026: The recovery is thinner than reported EBITDA suggests

Significant newsImerys' H1 looks better at first sight, but the recovery is thin. Reported EBITDA improved and Q2 showed a stronger margin, yet the wholly-owned business did not really move. The...

EssilorLuxottica: A hidden margin decline

Earnings/Sales releases Smart glasses development continues to erode margins. We will take a more conservative view of the company and revise our long-term margin assumptions. Fact Group...

Zensar Technologies Bets On AI, But Margins Need to Follow

Investors are watching whether Zensar Technologies Limited can convert demand into sustainable profit growth.

Can Exchange Income Corporation Capitalize on Aviation Industry's Long Runway?

Growing air traffic and fleet expansion support Exchange Income Corporation , although a sustained delivery is still required....

Amazon Still in Charge

The e-commerce giant has completed its $50bn investment in OpenAI.

Wall Street Bets Against the American Rare Earths Dream

North American rare earth producers have been in short sellers' crosshairs for the past few weeks.

DiaSorin: Q2 profitability beat and H2 launches reinforce credibility

Earnings/Sales releases DiaSorin's Q2 profitability surpassed expectations. Despite weak respiratory sales and challenges in China, revenue grew by mid-single digits. All segments experienced growth,...

Siemens Healthineers: Diagnostics impacted Q3 performance; Q4 core business outlook provides relief

Earnings/Sales releases Siemens Healthineers' Q3 sales slightly missed expectations, though profitability met forecasts. The Precision Therapy and Imaging segments reported growth, while Diagnostics...